NKGen Biotech announced that its CEO, Dr. Paul Y. Song, will present the company’s lead drug candidate, troculeucel, at the 2026 BIOCHINA Global Forum in Seoul. Troculeucel is an investigational natural killer cell therapy currently in Phase 2 trials for Alzheimer’s disease and is being explored for other neurodegenerative diseases like ALS, FTD, and Parkinson’s. The presentation will also cover regulatory opportunities in China that could support drug development and partnerships. This event highlights NKGen’s efforts to expand its global network for advancing and commercializing its therapies.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
